HINJ has submitted comments to the Department of Commerce regarding the Section 232 National Security Investigation on imports of pharmaceuticals and pharmaceutical ingredients. The comments were filed in response to a Federal Register notice requesting public input on potential tariffs affecting these products.
The organization expressed opposition to such tariffs, highlighting the complexities involved in research and development, manufacturing, and supply chains within the pharmaceutical industry. HINJ emphasized the industry’s significant role in global health and its contribution to America’s innovation economy.
In their statement, HINJ noted their commitment to collaborating with national and state trade organizations as well as member companies on related issues as they develop.
